AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

0 Umsagnir
0
Episode
786 of 1070
Lengd
29Mín.
Tungumál
enska
Gerð
Flokkur
Viðskiptabækur

Today's guest is Andrew Bolt, Partner at Deloitte. He joins Emerj CEO and Head of Research Daniel Faggella on today's podcast to talk about challenges in R&D for life sciences. While productivity has remained stagnant for the last 10-15 years, advances in AI-enhanced protein structure prediction are revolutionizing drug targeting and the very infrastructure of recruiting patients for clinical trials. Later, the two postulate on the ways AI can expedite regulatory compliance in pharmaceutical R&D in similar ways. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

Other podcasts you might like ...